Market Overview - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index rising by 1.08%, underperforming the CSI 300 Index by 0.03 percentage points, ranking 18th among 30 CITIC first-level industry indices [4][7]. - The top ten stocks by weekly gain include Kanghui Pharmaceutical, *ST Jingfeng, and Rongchang Bio, while the biggest losers include Beiyikang and Wuxi Jinghai [3][4]. Investment Themes - The pharmaceutical sector is currently undervalued, with public funds (excluding pharmaceutical funds) showing low allocation to this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories on the industry [7]. - In the innovative drug segment, there is a shift from quantity to quality, emphasizing differentiated and internationalized pipelines. Companies like Heng Rui, Bai Ji, and Bei Da are recommended for investment [7]. - The medical device market is witnessing a recovery in bidding volumes, particularly in imaging equipment, with companies like Mindray and United Imaging being highlighted. The home medical device market is also expected to benefit from subsidy policies [7]. - The CXO and life sciences services sector is anticipated to see a rebound in investment, with a focus on companies that can deliver high profit elasticity as they enter the return phase [7]. Traditional Chinese Medicine (TCM) Market - The retail sales of TCM are projected to remain stable, with a slight decline expected in 2024. The total retail sales are expected to reach 168 billion yuan, down 3.6% year-on-year [9][10]. - The top categories in TCM retail sales for 2024 include cold medicine, health supplements, and cardiovascular drugs, with notable products like Ganmao Ling Granules and Ejiao experiencing varying growth rates [15][19][24]. Specific Drug Categories - **Cold Medicine**: The retail sales are expected to decline by 8.4% in 2024, with the top product, Ganmao Ling Granules, showing a growth of 5.4% [20][21]. - **Health Supplements**: Despite a high base, the market is expected to see a slight decline, with Ejiao projected to drop by 13.4% [19][21]. - **Cardiovascular Drugs**: This category is experiencing its first decline in recent years, with a projected drop of 5.9% in 2024 [24]. - **Cough and Phlegm Relief**: Retail sales are expected to decrease by 4.3%, with products like Mi Lian Chuan Bei Pi Pa Gao showing a slight increase [29]. - **Gastrointestinal Drugs**: The market remains stable, with a projected decline of 3.4% in 2024 [33]. - **Musculoskeletal Drugs**: This category is expected to continue its downward trend, with a projected decline of 3.7% [36]. - **Urological Drugs**: The market has seen a significant decline, with a projected drop in sales [46]. - **Nervous System Drugs**: This category is expected to maintain stability, with a slight decline of 0.3% [48]. Conclusion - The pharmaceutical sector is navigating a complex landscape with varying performance across different categories. While some areas show promise for recovery and growth, others are facing challenges that could impact overall market sentiment and investment strategies [7][9][20][24].

证券研究报告|医药生物|2025年3月15日 www.hczq.com ERA | 01 | 行情回顾 | | --- | --- | | 02 | 板块观点和投资组合 | | 03 | 行业和个股事件 | 神经介入行业近况更新 本周专题联系人：李婵娟 张良龙 | 华创医药团队: | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号：S0360520120002 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号：S0360523080008 邮箱：wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com ...

Market Review - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 2.78%, underperforming the CSI 300 Index by 0.56 percentage points, ranking 21st among 30 primary industries [4] - The top ten stocks by growth this week include Nuo Cheng Jian Hua-U, Chang Yao Holding, and Shanghai Yi Zhong, with growth rates of 20.98%, 20.96%, and 18.78% respectively [3][4] - Conversely, the bottom ten stocks include Jiangsu Wu Zhong and Xin Gan Jiang, with declines of 4% and 6% respectively [4] Industry and Stock Events - The pharmaceutical sector's valuation is currently low, with public funds (excluding pharmaceutical funds) also underweight in this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories and products [7] - In the innovative drug segment, there is a shift from quantity logic to quality logic, emphasizing the importance of product differentiation and internationalization. Companies to watch include Heng Rui, Bai Ji, and Nuo Cheng Jian Hua [7] - The medical device sector is expected to benefit from the acceleration of equipment renewal policies, with key companies like Mai Rui Medical and Xin Hua Medical positioned to gain from increased orders [7] - The IVD market is anticipated to return to high growth, with a focus on companies like An Tu Biology and Di Rui Medical, as domestic market penetration continues to expand [7] - The blood products sector is set for growth, with a favorable regulatory environment for plasma collection and increasing demand post-pandemic. Companies such as Tian Tan Biology and Bo Ya Biology are recommended [12] Antibiotics Industry Update - The global antibiotic market is projected to grow steadily, with a market size of approximately 98 billion yuan in China from 2017 to the third quarter of 2024. The top three hospital antibiotics in 2024 are expected to be injectable formulations of Piperacillin and Tazobactam, with sales of 4.94 billion yuan [15][16] - The production capacity for key antibiotic intermediates is under strict regulatory control, with the latest guidelines from the National Development and Reform Commission continuing to restrict new capacity in antibiotic intermediates [17] - The price trends for key antibiotic products such as Penicillin and 6-APA have shown fluctuations, with 6-APA's price reaching 320 yuan per kilogram by January 2025 [24][25]